Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2017 in advanced malignant solid tumors
NCT07274085Phase 1Recruiting
- Sponsor
- Huadong Medicine
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of HDM2017 in solid tumor, sponsored by Huadong Medicine. Primary endpoints: Maximum Tolerated Dose at 30 days, Recommended Phase 2 Dose at 30 days and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
HDM2017
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07274085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274085.